When a university spinout raises its first outside capital, the technology transfer office (TTO) and founding academics almost always choose between two short-form instruments rather than negotiating a priced equity round: a SAFE (Simple Agreement for Future Equity) or a convertible note. Both defer the question of “what is this company actually worth” to a later financing event, and both convert into preferred equity rather than paying cash back in the ordinary case. But they are legally different instruments with different mechanics, different risk allocation, and different implications for a university’s own equity stake and its institutional policies. This guide compares the two directly — discount, cap, maturity, and conversion trigger — for the specific context of a university-affiliated spinout, where a TTO’s existing license and equity terms, and often a public institution’s own contracting rules, add constraints a typical startup lawyer’s generic SAFE-vs-note explainer does not cover.
For the broader menu of early capital sources (SBIR/STTR, gap funds, licensing income, VC), see Funding Options for a University Spinout. For how a SAFE or note round affects the university’s and founders’ percentage ownership over time, see Equity Dilution for Academic Founders. For how the university’s initial equity stake is set at formation, before any outside seed money is raised, see University Spinout Equity Split.
The shared idea: deferring valuation to a priced round
Both instruments exist to solve the same problem: at the seed stage, a spinout is too early to price fairly. Pricing a round requires a valuation, and a pre-revenue company built around a single license or a handful of patent applications is difficult to value with any precision. Rather than negotiate a share price now, a SAFE or convertible note lets an investor put money in today in exchange for the right to receive equity later, at or before the company’s first priced financing (typically a Series A led by an institutional venture investor), on terms that reward the early investor for having taken on more risk, earlier.
Both instruments typically carry two economic terms that do that reward-setting work:
- Valuation cap — the maximum company valuation at which the investor’s money converts into shares. If the priced round values the company above the cap, the SAFE/note holder still converts as if the company were only worth the cap amount, giving them more shares (a lower effective price per share) than new investors in that round pay.
- Discount rate — a straight percentage reduction (commonly 15–20%) off the per-share price of the priced round, applied instead of, or in some templates alongside, the cap.
Where a cap and discount are both present, the investor’s instrument almost always converts at whichever produces more shares for the same dollar invested (the more investor-favorable outcome) — a “cap or discount, whichever is lower effective price” mechanic worth confirming explicitly in the document’s conversion-price definition, since it is not always spelled out the same way twice.
SAFE mechanics
The SAFE was introduced by the startup accelerator Y Combinator in 2013 and has since become the dominant seed-stage instrument in the U.S. market. A SAFE is not debt. It carries no interest rate, no maturity date, and no repayment obligation of any kind — if the company never raises a priced round, is acquired below the cap, or fails outright, the SAFE simply never converts into equity and the investor has no contractual right to demand their money back (this is precisely why the instrument is legally structured as a purchase of a future equity right, not a loan). Y Combinator’s own current template library offers three variants — cap-only, discount-only, and MFN-only (Most Favored Nation, meaning the investor’s terms automatically upgrade to match whatever better terms a later SAFE investor in the same round receives) — all using post-money valuation math, meaning the cap is expressed as the company’s valuation immediately after the SAFE round closes, which makes the resulting dilution to existing holders calculable at the time of signing rather than only after the fact.
A SAFE converts on one of a small number of defined trigger events, spelled out in the agreement itself:
- An equity financing that meets the agreement’s definition of a qualifying priced round (usually a minimum raise amount with new investors and a lead who sets the price).
- A liquidity event — an acquisition, change of control, or IPO — before any qualifying financing has occurred, in which case the SAFE typically pays out as either the greater of the investor’s cap-adjusted equity value or their original investment amount, depending on the template.
- Dissolution of the company, where SAFE holders generally rank ahead of common stockholders but behind actual creditors, similar to how preferred stock is treated.
Because there is no maturity date, there is no point at which a SAFE forces a conversation the company doesn’t want to have — which is exactly the tradeoff a university weighing the instrument needs to understand: the absence of a forcing mechanism is a benefit to the company’s runway and a real, occasionally material, limitation on the investor’s (and, if the university itself holds a SAFE from a licensee-founded spinout, the university’s) ability to compel a resolution if the company simply stalls indefinitely without failing outright.
Convertible note mechanics
A convertible note is, first and legally, a debt instrument — a loan the company must repay, carrying a stated interest rate (commonly in the mid-single-digit percent range, accruing but rarely paid in cash before conversion) and a fixed maturity date, typically 18–24 months from issuance. Like a SAFE, it usually carries a valuation cap and/or discount that governs the conversion price if a qualifying equity financing happens before maturity. The material difference is what happens if that qualifying financing has not happened by the maturity date: depending on what the note itself specifies, the company and noteholders must either (a) agree to extend the maturity date, (b) convert the note into equity at a valuation set by the note’s own terms (sometimes a separate, lower “maturity cap,” or the last valuation on which the company raised), or (c) the noteholder can technically demand repayment of principal plus accrued interest — a right that is rarely exercised against an early-stage company with limited cash, but is a real, negotiated legal right the SAFE structure simply does not create.
Because a convertible note is debt, it also interacts with a company’s balance sheet, and with any subsequent institutional lender or licensor, differently than a SAFE does — it is a liability, it can (depending on state law and the note’s own subordination language) affect the company’s standing relative to other creditors, and noteholders as creditors technically have priority over all equity holders, including preferred stockholders, in a liquidation or dissolution before any conversion has occurred.
Side-by-side comparison
| Dimension | SAFE | Convertible note |
|---|---|---|
| Legal form | Equity-right purchase agreement (not debt) | Debt instrument (a loan) |
| Interest | None | Yes — a stated annual rate, accrues to principal at conversion |
| Maturity date | None — no forced deadline | Yes — typically 18–24 months; triggers repayment demand, forced conversion, or renegotiation if no priced round has occurred |
| Valuation cap / discount | Yes, in most templates (cap-only, discount-only, or both depending on template) | Yes, functionally equivalent economic mechanics |
| Conversion trigger | Qualifying equity financing, liquidity event, or dissolution | Qualifying equity financing (before maturity), or maturity itself (repay, convert, or extend) |
| Priority if company fails | Ranks ahead of common stock, behind actual creditors | Ranks as a creditor — ahead of all equity, including preferred, until conversion |
| Legal/drafting complexity and cost | Lower — standard 5-page template, minimal negotiation in most seed rounds | Moderate — longer document, more negotiated terms (interest rate, maturity, default remedies) |
| Forces a resolution? | No — can remain outstanding indefinitely if no trigger occurs | Yes — maturity date forces the company, TTO, and investors to act |
| Typical use case | Fast, low-friction pre-seed/seed closes; the current market default for U.S. seed rounds | Rounds where investors want a hard deadline and creditor-level protection, or in jurisdictions/institutions where an equity-purchase instrument is administratively harder to execute than a loan |
Why the choice matters more for a university spinout than for a typical startup
The university’s own equity stake is a stakeholder in the outcome
Most university spinouts are formed around an exclusive license under which the institution itself holds founder-stage equity (see University Spinout Equity Split). A SAFE or note round issued after that license is in place dilutes the university’s stake exactly as it dilutes the founders’ — the cap and discount terms an outside investor negotiates directly set how much of that dilution the university absorbs at the next priced round. A TTO reviewing a term sheet is not a disinterested observer of the cap number; it is, in effect, negotiating its own future ownership percentage by proxy.
Public-institution and state-law constraints
Some public universities and state-affiliated research institutions operate under procurement, contracting, or state-finance rules that were not written with either instrument in mind, and general counsel review is standard practice before a TTO or an affiliated foundation signs, or permits a spinout it holds equity in to issue, either instrument. A convertible note’s debt character can raise different institutional questions (state restrictions on the institution acting as, or being subordinate to, a creditor relationship) than a SAFE’s equity-purchase-right character does — which of the two is administratively simpler varies by institution and is not consistent across systems, so this is a genuine “check with your institution’s general counsel and finance office” point rather than one with a universal answer.
Timing against the license and any existing gap funding
Spinouts that have already drawn on proof-of-concept or gap funding (see Funding Options for a University Spinout) sometimes issue a SAFE or note to convert that internal funding into a formal instrument alongside new outside money, on the same or side-letter terms. Coordinating the cap across an internal gap-fund conversion and a new outside SAFE/note round — so the university and TTO are not inadvertently accepting worse terms on its own prior investment than a new external investor gets — is a detail worth confirming explicitly in the round documents rather than assuming consistency.
Stacking multiple rounds
It is common for an early spinout to raise more than one SAFE or note round before its first priced equity round — a pre-seed SAFE, then a seed SAFE at a higher cap, for instance. Each has its own cap/discount and converts into the priced round independently unless the documents specify otherwise; the cumulative dilution across a stack of instruments is exactly the mechanic covered in Equity Dilution for Academic Founders, and a TTO or founder team should model the fully-converted cap table under a stack of instruments, not just the most recent one, before agreeing to a new cap.
Which instrument do investors and spinouts actually use
The SAFE has become the default instrument for U.S. pre-seed and seed rounds generally, reflecting its lower legal cost and faster close; convertible notes remain common where an investor specifically wants the creditor-level protection and forced-resolution mechanism a maturity date provides, or in earlier-stage friends-and-family or angel rounds preceding a company’s first institutional SAFE or priced round. Neither instrument is a CASRAI or federal standard — the terms above track the market-standard Y Combinator SAFE template and the National Venture Capital Association’s model convertible note documents, which most institutional investors and startup counsel use as a starting point for negotiation. A TTO’s own institutional policy, its general counsel, and the specific term sheet in front of it always govern over any generic description of “how these instruments usually work,” including this one.
Frequently asked questions
Is a SAFE the same as equity?
Not until it converts. A SAFE is a contractual right to receive equity in the future, upon a defined trigger event; the investor holds no shares, no voting rights, and no dividend rights until conversion actually occurs.
Do SAFEs and convertible notes dilute the university’s stake the same way?
Mechanically, yes — both convert into new shares at the priced round using the same cap/discount math, and both dilute every existing holder, including the university, proportionally at conversion. The difference is timing and forcing mechanism, not the dilution math itself once conversion happens.
What happens if a convertible note reaches maturity and the company hasn’t raised a priced round?
The note documents govern, and outcomes vary: common resolutions are a negotiated extension of the maturity date, a forced conversion into equity at a valuation set by the note’s own terms, or, rarely for an early-stage company with limited cash, a repayment demand. This is exactly the scenario a SAFE structurally cannot produce, since it has no maturity date to reach.
Can a SAFE and a convertible note be used in the same seed round?
Yes — it is common for a company to have issued an earlier note or SAFE and then raise additional capital on a new SAFE, or vice versa; each instrument converts according to its own terms unless the documents are explicitly amended to align them.
Does the choice of instrument affect the founders’ or university’s 83(b) election obligations?
No — 83(b) elections relate to restricted stock actually issued to founders (or, separately, to the university under its license), not to SAFEs or notes themselves, which are not stock and create no 83(b) timing obligation until they convert.
This guide is general reference material on standard market instruments and does not constitute legal or financial advice. TTOs, founders, and investors should confirm final terms with qualified securities counsel and, for public or state-affiliated institutions, with institutional general counsel before signing.
